Under the terms of the agreement, PolyTherics’s proprietary drug modification technologies will be used to enhance certain of the innovative pharmaceutical products being developed by Celtic Pharma. The companies plan to jointly develop and validate modifications of drugs submitted to the collaboration by Celtic Pharma, in order to improve their performance and assess their future development potential.
Keith Powell, CEO of PolyTherics, said: “The opportunity to collaborate with a high calibre, product-focused company such as Celtic Pharma is a significant milestone in the development of PolyTherics, and we are delighted to be working with Celtic Pharma on several of the products in their portfolio.”